Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
| Cat.No. | Product Name | Price |
|---|---|---|
| CSC-DC015536 | Panoply™ Human TACSTD2 Knockdown Stable Cell Line | Inquiry |
| CSC-SC015536 | Panoply™ Human TACSTD2 Over-expressing Stable Cell Line | Inquiry |
| CSC-RO0483 | Human TACSTD2 Stable Cell Line - CHO-K1 | Inquiry |
| CLOE-1414 | Human TACSTD2 HEK293 Cell Lysate | Inquiry |
| CLOE-1417 | Human TACSTD2(His) HEK293 Cell Lysate | Inquiry |
| CLOE-2398 | Mouse Tacstd2 HEK293 Cell Lysate | Inquiry |
| CLOE-2399 | Mouse Tacstd2(Fc) HEK293 Cell Lysate | Inquiry |
| CSC-RO0542 | Human TACSTD2 Stable Cell Line - HEK293T | Inquiry |
| CSC-RO0915 | Human TACSTD2 Stable Cell Line - PC3 | Inquiry |
| CSC-RH0189M | Humanized TACSTD2 Murine Tumor Cell Line | Inquiry |
| CSC-RO01309 | Human TACSTD2 Stable Cell Line - T24 | Inquiry |
| CSC-RO01398 | Monkey TACSTD2 Stable Cell Line - CHO-K1 | Inquiry |
| CSC-RO01399 | Mouse Tacstd2 Stable Cell Line - CHO-K1 | Inquiry |
| CSC-RO02520 | Human TACSTD2 Stable Cell Line - HEK293 | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| AD15886Z | Human Tacstd2 adenoviral particles | Inquiry |
| LV27224L | human TACSTD2 (NM_002353) lentivirus particles | Inquiry |
| LVG00067Z | scFv(TACSTD2)-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00068Z | scFv(TACSTD2)-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00069Z | scFv(TACSTD2)-CD28-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00070Z | scFv(TACSTD2)-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00071Z | scFv(TACSTD2)-CD28-41BB-CD3zeta CAR-T Lentivirus | Inquiry |
| LVG00072Z | scFv(TACSTD2)-CD28-OX40-CD3zeta CAR-T Lentivirus | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| SHH422500 | shRNA set against Mouse Tacstd2 (NM_020047.3) | Inquiry |
| SHL053928 | shRNA set against Human TACSTD2(NM_002353.2) | Inquiry |
| SHL053974 | shRNA set against Mouse Tacstd2(NM_020047.3) | Inquiry |
| SHH422504 | shRNA set against Rat Tacstd2 (NM_001009540.2) | Inquiry |
| SHL053992 | shRNA set against Rat Tacstd2(NM_001009540.2) | Inquiry |
| SHW003996 | shRNA set against Chicken TACSTD2 (NM_001277676) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| RP00447 | Recombinant Human TACSTD2 (248AA, C-6His) | Inquiry |
| RP00450 | Recombinant Human TACSTD2 (C-6His) | Inquiry |
| RP00486 | Recombinant Human TACSTD2 (248AA, C-Fc) | Inquiry |
| RP00504 | Biotinylated Human TACSTD2 (C-Avi-6His) | Inquiry |
| RP00507 | Recombinant Human TACSTD2 (C-Fc) | Inquiry |
| RP00515 | Recombinant Mouse Tacstd2 (C-6His) | Inquiry |
| RP00518 | Recombinant Rhesus Macaque TACSTD2 (C-6His) | Inquiry |
| Cat.No. | Product Name | Price |
|---|---|---|
| CDCL186371 | Mouse TACSTD2 ORF clone(NM_020047.3) | Inquiry |
| CDCS410755 | Human TACSTD2 ORF Clone (BC009409) | Inquiry |
| CDFL013402 | Mouse Tacstd2 cDNA Clone(NM_020047.3) | Inquiry |
| CDFR002195 | Rat Tacstd2 cDNA Clone(NM_001009540.2) | Inquiry |
| MiUTR1H-10149 | TACSTD2 miRNA 3'UTR clone | Inquiry |
| MiUTR1M-11492 | TACSTD2 miRNA 3'UTR clone | Inquiry |
| MiUTR1R-07878 | TACSTD2 miRNA 3'UTR clone | Inquiry |
| CDCB165471 | Chicken TACSTD2 ORF Clone (NM_001277676) | Inquiry |
| CDCB194768 | Rabbit TACSTD2 ORF clone (XM_008265178.1) | Inquiry |
| CDCL186632 | Human TROP2 ORF clone(NM_002353.2) | Inquiry |
| CDCR369207 | Rat Tacstd2 ORF Clone(NM_001009540.2) | Inquiry |
TACSTD2 (Tumor-Associated Calcium Signal Transducer 2), also known as TROP2, is located on human chromosome 1p32.1 and encodes a single-pass transmembrane glycoprotein, which belongs to the epithelial cell adhesion molecule (EPCAM) family. The structure of TROP2 includes an extracellular domain (containing tyrosine phosphorylation sites), a transmembrane region, and a cytoplasmic tail (containing a PI3K/AKT binding motif). TROP2 regulates cell-matrix adhesion through calcium ion signaling, and its expression is positively regulated by the Wnt/β-catenin signaling pathway. During embryonic development, TROP2 is involved in tissue morphogenesis, and in adult tissues, it is primarily expressed in regenerative tissues such as the cornea and intestinal epithelium.
The dysfunction of TACSTD2 is associated with two distinct types of diseases. First, mutations in TACSTD2 are linked to corneal dystrophy, where mutations lead to protein misfolding and amyloid deposition beneath the corneal epithelium. Clinically, this results in the formation of grayish-white gelatinous nodules on the corneal surface and progressive vision loss, which is particularly prevalent in Asian populations. Secondly, TROP2 is overexpressed in various malignancies, especially in bladder cancer, where its expression level exceeds 90%. The oncogenic mechanism of TROP2 includes activating the PI3K/AKT/mTOR pathway to inhibit apoptosis, promoting the transcription of cell cycle protein Cyclin D1, and forming complexes with integrin β1–Claudin-7, which aids in tumor invasion and metastasis.
TROP2 expression is closely associated with tumor molecular subtypes. For instance, in bladder cancer, TROP2 levels are significantly higher in the urothelial carcinoma subtype compared to the squamous differentiation subtype, while neuroendocrine-like tumors exhibit a loss of expression.
Figure 1. Trop2-mediated intracellular and extracellular signaling pathways. (Liu X, et al., 2022)
Due to the high expression of TROP2 in various cancers, it has become a prominent target for antibody-drug conjugates (ADC). Sacituzumab Govitecan (SG), an ADC consisting of an anti-TROP2 monoclonal antibody conjugated to the topoisomerase inhibitor SN-38, has shown significant therapeutic efficacy in metastatic triple-negative breast cancer (mTNBC). The objective response rate (ORR) was 35%, and the median overall survival (OS) was extended to 14.4 months, compared to 11.2 months in the chemotherapy group. In non-small cell lung cancer (NSCLC), another TROP2-targeting ADC, Datopotamab Deruxtecan (Dato-DXd), showed a significant improvement in progression-free survival (PFS) with a lower incidence of interstitial lung disease compared to similar drugs.
In addition to cancer treatment, gene therapy strategies are exploring how to correct TACSTD2 mutations. Using adeno-associated virus (AAV) vectors to deliver the wild-type TACSTD2 gene into the cornea in a GDLD mouse model successfully reduced amyloid deposits by 50%, providing a potential approach for treating genetic corneal diseases.
Despite the promising potential of TROP2-targeted therapies, there are several challenges to address. First, the physiological expression of TROP2 in normal tissues, particularly in the intestinal epithelium, may lead to tissue toxicity, as seen with SG, where 11% of patients experienced severe diarrhea. Additionally, the internalization efficiency of ADCs may be compromised by the glycosylation modifications of TROP2. In bladder cancer, about 18.4% of tumors exhibit low TROP2 expression, which results in reduced internalization and decreased therapeutic response. Therefore, developing conditional activation antibodies or optimizing drug delivery systems could help improve therapeutic specificity and reduce side effects.
Future research should focus on the interaction between TROP2 and the immune microenvironment, exploring the co-expression of TROP2 and immune checkpoint molecules (e.g., PD-L1) to support the development of ADC-immunotherapy combination strategies. Additionally, integrating genomic and transcriptomic data to predict ADC responsiveness based on tumor subtypes (e.g., basal-like vs. luminal) and utilizing artificial intelligence to design more selective treatments could become key strategies for advancing TROP2-targeted therapies.
In conclusion, TROP2 plays a critical role in cancer cell proliferation, invasion, and metastasis and holds potential as a therapeutic target not only in cancer but also in genetic corneal diseases. As research advances in understanding its biological functions and developing more precise treatment strategies, TROP2 could become a pivotal target in both oncology and gene therapy, improving the treatment outcomes of various diseases.
Reference
Liu X, Deng J, Yuan Y, et al. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022 Nov;239:108296.
Liu X, Ma L, Li J, et al. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024 Jun 11;14(9):3674-3692.